Swiss medicines regulator Swissmedic has approved Coartem Baby, a Novartis anti-malaria drug developed for infants weighing between two and five kilos. +Get the most important news from Switzerland in your inbox This is a significant step in global efforts to improve access to life-saving treatments for vulnerable populations, Swissmedic wrote in a statement today. The product fills a serious treatment gap for one of the most vulnerable patient groups. + Switzerland's global role in fighting malaria The availability of a treatment specifically designed for girls and young children marks an important step forward in the global fight against malaria. The approval process for the product - also known as Riamet Baby in some countries - involved close collaboration with the national regulatory authorities of eight African countries: Burkina Faso, Ivory Coast, Kenya, Malawi, Mozambique, Nigeria, Uganda and Tanzania. The Global Malaria Programme of the World Health Organisation (WHO) also ...
